GLP-1 Weight-Loss Pills Could Transform Treatment
A new era of weight-loss treatment could soon trade needles for pills. Drugmakers behind GLP-1 injections like Wegovy…
Drug firm publishes clinical trials tripling Ozempic dose for greater weight loss – The Journal
Drug firm publishes clinical trials tripling Ozempic dose for greater weight loss The Journal Triple-strength ‘mega-dose’ of slimming jab…
How the ‘Ozempic effect’ is reshaping the global economy
Michael Siluk/Alamy The new wave of weight-loss drugs has taken the world by storm. From Novo Nordisk’s Ozempic…
2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades
The overall stock market keeps reaching new heights, but some of its components are having a lousy year.…
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative…
Weight-loss drugs becoming better value for money, says watchdog
Popular GLP-1 weight-loss injections are now delivering greater value, according to a new report by a leading pharmaceutical…
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…
Pricing group says weight-loss drugs becoming more cost-effective
By Deena Beasley (Reuters) -An influential drug pricing watchdog on Tuesday said popular GLP-1 weight-loss injections have become…
The Ozempic effect: From shopping baskets to dips in Danish GDP
ADVERTISEMENT Denmark sliced its 2025 economic growth forecast in half recently after a cool-down at Novo Nordisk, the…
Drugmaker halves price of Ozempic for Americans amid Trump crackdown
The maker of Ozempic is halving the price of its weight-loss jabs in the US after Donald Trump…
Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
Ozempic® is the first-and-only medication indicated for both the once-weekly treatment of adult patients with type 2 diabetes…
Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made…